JasonBrayerMDPhD

PubMed

• Lenalidomide-based response-adapted therapy for older adults without high risk myeloma.
  Baz, R.,Naqvi, SMH.,Lee, J. H.,Brayer, J.,Hillgruber, N.,Fridley, B. L.,Shain, K. H.,Sullivan, D. M.,Alsina, M.> ;Br. J. Haematol.. 2018 Dec 15
• OMIP-049: Analysis of Human Myelopoiesis and Myeloid Neoplasms.
  Zhu, G.,Brayer, J.,Padron, E.,Mulé, J. J.,Mailloux, A. W.> ;Cytometry A. 2018 Oct 23
• The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.
  Brayer, J.,Baz, R.> ;Ther Adv Hematol. 2017 Jul 12
• WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides.
  Brayer J, Lancet JE, Powers J, List A, Balducci L, Komrokji R, Pinilla-Ibarz J> ;Am J Hematol. 2015 Jul
• Transformation to Hodgkin lymphoma in chronic lymphocytic leukemia coexisting with Epstein-Barr viremia.
  Dalia S, Brayer J, Horna P, Zhang H, Pinilla-Ibarz J> ;Leuk Lymphoma. 2014 Nov
• Regression of metastatic clear cell kidney cancer with interleukin-2 treatment following nivolumab (anti-PD-1) treatment.
  Jason Brayer, Mayer Fishman> ;Journal of Immunotherapy. 2014 Apr 1
• Developing strategies in the immunotherapy of leukemias.
  Brayer JB, Pinilla-Ibarz J> ;Cancer Control. 2013 Jan
• Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3.
  Brayer J, Cheng F, Wang H, Horna P, Vicente-Suarez I, Pinilla-Ibarz J, Sotomayor EM> ;Immunol Lett. 2010 Jul 8
• TLR5 ligation by flagellin converts tolerogenic dendritic cells into activating antigen-presenting cells that preferentially induce T-helper 1 responses.
  Vicente-Suarez I, Brayer J, Villagra A, Cheng F, Sotomayor EM> ;Immunol Lett. 2009 Aug 15
• In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity.
  Horna P, Cuenca A, Cheng F, Brayer J, Wang HW, Borrello I, Levitsky H, Sotomayor EM> ;Blood. 2006 Apr 1
• Expansion of Myeloid Suppressor Cells in SHIP-Deficient Mice Represses Allogeneic T Cell Responses
  Tomar Ghansah, Kim H. T. Paraiso, Steven L. Highfill, Caroline Desponts, Sarah May, Joseph K. McIntosh, Jia-Wang Wang, John M. Ninos, Jason Brayer, Fengdong Cheng, Edu...> ;Journal of Immunology. 2004 Dec 15
• A dual role for interferon-gamma in the pathogenesis of Sjogren's syndrome-like autoimmune exocrinopathy in the nonobese diabetic mouse.
  Cha S, Brayer J, Gao J, Brown V, Killedar S, Yasunari U, Peck AB> ;Scand J Immunol. 2004 Dec
• Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses
  Paulo C. Rodriguez, David G. Quiceno, Jovanny Zabaleta, Blair Ortiz, Arnold H. Zea, Maria Blanca Piazuelo, Alberto G. Delgado, Pelayo Correa, Jason Brayer, Eduardo M. ...> ;Cancer Research. 2004 Aug 15
• Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to...
  Cuenca A, Cheng F, Wang H, Brayer J, Horna P, Gu L, Bien H, Borrello IM, Levitsky HI, Sotomayor EM> ;Cancer Res. 2003 Dec 15
• A critical role for Stat3 signaling in immune tolerance.
  Cheng F, Wang HW, Cuenca A, Huang M, Ghansah T, Brayer J, Kerr WG, Takeda K, Akira S, Schoenberger SP, Yu H, Jove R, Sotomayor EM> ;Immunity. 2003 Sep
• Immunogenetics of autoimmune exocrinopathy in the nod mouse: more than meets the eye.
  Humphreys-Beher MG, Brayer J, Cha S, Nagashima H, Diggs S, Peck AB> ;Adv Exp Med Biol. 2002
• Sjogren's syndrome: immunological response underlying the disease.
  Brayer JB, Humphreys-Beher MG, Peck AB> ;Arch Immunol Ther Exp (Warsz). 2001
• Abnormal organogenesis in salivary gland development may initiate adult onset of autoimmune exocrinopathy.
  Cha S, van Blockland SC, Versnel MA, Homo-Delarche F, Nagashima H, Brayer J, Peck AB, Humphreys-Beher MG> ;Exp Clin Immunogenet. 2001
• IL-4-dependent effector phase in autoimmune exocrinopathy as defined by the NOD.IL-4-gene knockout mouse model of Sjogren's syndrome.
  Brayer JB, Cha S, Nagashima H, Yasunari U, Lindberg A, Diggs S, Martinez J, Goa J, Humphreys-Beher MG, Peck AB> ;Scand J Immunol. 2001 Jul-Aug
• Differential absorption and distribution of epidermal growth factor and insulin-like growth factor in diabetic NOD mice.
  Clarke MY, Brayer J, Heintz K, Nagashima H, Cha S, Oxford GE, Nanni JM, Peck AB, Zelles T, Humphreys-Beher MG> ;J Diabetes Complications. 2001 Mar-Apr
• Elevated proapoptotic Bax and caspase 3 activation in the NOD.scid model of Sjogren's syndrome.
  Masago R, Aiba-Masago S, Talal N, Zuluaga FJ, Al-Hashimi I, Moody M, Lau CA, Peck AB, Brayer J, Humphreys-Beher MG, Dang H> ;Arthritis Rheum. 2001 Mar
• Alleles from chromosomes 1 and 3 of NOD mice combine to influence Sjogren's syndrome-like autoimmune exocrinopathy.
  Brayer J, Lowry J, Cha S, Robinson CP, Yamachika S, Peck AB, Humphreys-Beher MG> ;J Rheumatol. 2000 Aug
• Evidence for antimuscarinic acetylcholine receptor antibody-mediated secretory dysfunction in nod mice.
  Nguyen KH, Brayer J, Cha S, Diggs S, Yasunari U, Hilal G, Peck AB, Humphreys-Beher MG> ;Arthritis Rheum. 2000 Oct
• Aberrant proteolytic digestion of biglycan and decorin by saliva and exocrine gland lysates from the NOD mouse model for autoimmune exocrinopathy.
  Yamachika S, Brayer J, Oxford GE, Peck AB, Humphreys-Beher MG> ;Clin Exp Rheumatol. 2000 Mar-Apr
• An alternative perspective to the immune response in autoimmune exocrinopathy: induction of functional quiescence rather than destructive autoaggression.
  Humphreys-Beher MG, Brayer J, Yamachika S, Peck AB, Jonsson R> ;Scand J Immunol. 1999 Jan
• Join now to see all

Abstracts/Posters

• Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis...
  Jason B. Brayer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
  Jason B. Brayer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma
  Jason B. Brayer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Composition of Immune Subpopulations Influence Multiple Myeloma Disease Progression
  Jason B. Brayer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018